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In this issue of Cancer Cell, Riggi and colleagues use a genomic approach to define two distinct molecular
mechanisms through which the chimeric EWS/FLI1 oncoprotein regulates target genes in Ewing sarcoma,
expanding a framework upon which to model the target gene network and test strategies for antagonizing
growth of this tumor.Twenty two years ago, Delattre and
Thomas pried open the door on Ewing
sarcoma biology by reporting that the
t(11,22) found in the large majority of
these tumors created a fusion gene be-
tween EWS and FLI1 (Delattre et al.,
1992). Finally, there was an unambiguous
biomarker for a malignancy that, up until
then, had been diagnosed primarily by
exclusion. Of even greater importance
was the prevalent belief that a somatic
mutation that was present in 85% of Ew-
ing tumors must be playing crucial onco-
genic roles. This contention was quickly
born out. Not only could ectopic expres-
sion of EWS/FLI1 avidly transform cells,
but inhibition of the fusion consistently
induced growth arrest of Ewing sarcoma
tumor derived cell lines. Who could ask
for a better therapeutic target for this
deadly disease?
And then things got difficult. Structural
function analyses of EWS/FLI1 indicated
that the fusion was mediating its biologic
effects by acting as an aberrant transcrip-tion factor. However, the portion of EWS
that was fused to FLI1 was found to be un-
structured, making it poor bait for protein
interaction screens and a difficult target
to develop small molecule antagonists
against (Ng et al., 2007). EWS/FLI1, like
many of the oncogenic chimeric fusions
found in other sarcomas, earned the ‘‘un-
druggable’’ label. The fact that in the last
two decades there has been only one
candidate small molecule that specifically
targets the EWS/FLI1 fusion, suggests
that, at least so far, this reputation is
deserved (Barber-Rotenberg et al., 2012).
So, if directly antagonizing EWS/FLI1
seemed unfeasible, perhaps targeting
genes that were transcriptionally modu-
lated by the fusion would be a therapeuti-
cally more tractable strategy. As molecu-
lar methods advanced, the number of
EWS/FLI1 target genes that were identi-
fied geometrically increased. The prob-
lem was that demonstrating biologic
relevance of these candidates proved to
be labor intensive, unpredictable, andincomplete. In general, forced expression
of any single EWS/FLI1 target gene did
not recapitulate the EWS/FLI1 phenotype
in cells. Conversely, target gene inhibition
frequently did not completely shut down
the cell transformation effects of EWS/
FLI1.
This suggested that EWS/FLI1 trans-
formed cells through the cumulative effect
of transcriptionally modulating a network
of genes. Inherent in such systems is a
central robustness that can tolerate loss
of oneormorenodeswhile stillmaintaining
the overall effect of the network (Friedman
and Perrimon, 2007). As success in the
search for EWS/FLI1’s Achilles heel was
proving progressively more unlikely, the
need to generate a comprehensive map
of the target gene network became more
urgent. Although earlier work provided
snapshots of this network, it was difficult
to paste the pictures together into a
coherent whole. What was needed was a
wide-angle lens through which to view
the broad EWS/FLI1 target gene network.ovember 10, 2014 ª2014 Elsevier Inc. 595
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approaches using high-throughput
sequencing technologies may provide
this sorely needed perspective. In this
issue of Cancer Cell, Riggi et al. (2014)
demonstrate that EWS/FLI1 target genes
can be parsed into two groups: (1) genes
that are upregulated by EWS/FLI1 primar-
ily through interacting with GGAA re-
peats present in satellite DNA within the
genome and (2) genes that are downregu-
lated by EWS/FLI1, whose regulatory re-
gions contain canonical ETS-binding sites
normally bound by ETS factors and that,
in Ewing sarcoma, are displaced by the
fusion. While some of these data echo
previous findings from other investigative
groups, the power of this current study
is in its broad scope. By assessing EWS/
FLI1 occupancy at target gene regulatory
sites along with co-factor occupancy
and histone modification, broad trends
are coming to light that can serve as a
logical framework describing the EWS/
FLI1 target gene network.
Particularly intriguing is the further vali-
dation that EWS/FLI1 can use GGAA re-
peats as genomic response elements.
This observation, first made by Gangwal
et al. (2008), prompted a fundamental
mechanistic insight into the relative sus-
ceptibility of developing Ewing sarcoma.
They posited that perhaps the very low596 Cancer Cell 26, November 10, 2014 ª20incidence of Ewing sarcoma in the African
population is due to differences in GGAA-
containing satellite DNA polymorphisms.
The further development by Riggi et al.
(2014) that, in binding GGAA repeats,
EWS/FLI1 can then imbue them with
enhancer-like qualities confirms at a mo-
lecular level another long-held belief that
EWS/FLI1 is more than the sum of its
parts. Functioning as a true chimera,
EWS/FLI1 can do what neither normal
EWS nor FLI1 can do.
While Riggi et al. (2014) provide an
initial view into the broad EWS/FLI1 tar-
get gene landscape, further refinement
can be anticipated. It seems likely that
not all genes that are transcriptionally
modulated by EWS/FLI1 promote onco-
genesis in Ewing sarcoma. Distinguishing
the pathophysiologically significant sub-
set from the incidental targets will be a
challenge. In this regard, fusion of large
data sets generated by this and other par-
allel studies could help to further refine
EWS/FLI1 target gene network models
(Wang et al., 2012).
Functionally inhibiting the EWS/FLI1
oncogenic program in a therapeutically
meaningful way still seems like a daunting
proposition. Simultaneous inhibition of
the correct combination of target genes
will likely be necessary to bring down
this network. The hope that studies such14 Elsevier Inc.as Riggi et al. (2014) inspire is that, in
describing the system, it can now be stra-
tegically navigated. With the advent of
such tools, the era of generating therapies
to combat Ewing sarcoma based on
educated guess and empiric intuition will
hopefully draw to a close.REFERENCES
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Plexiform neurofibromas are one of themost common tumors encountered in individuals with the neurofibro-
matosis type I (NF1) cancer predisposition syndrome. In this issue ofCancer Cell, Chen and colleagues define
the cell of origin for murine Nf1 plexiform neurofibroma and leverage this finding to develop a platform for
preclinical drug evaluation.Neurofibromatosis type I (NF1) is one of
the most common cancer predisposition
syndromes, affecting 1 in 2,500 individ-
uals worldwide (Lin and Gutmann, 2013).Among the diverse number of benign
and malignant neoplasms observed in
this condition, peripheral nerve sheath
tumors (neurofibromas) are found innearly all adults with NF1. One subtype
of neurofibroma, the plexiform neurofi-
broma, is a particularly challenging tumor
to manage. These extensive, highly
